Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OSE ImmunotherapeuticsORPOF 51 3-1 Month Momentum % is -61.81% as of Jul. 25, 2026. GuruFocus rates ORPOF with a GF Score™ of 51/100 and a GF Value™ of $2.06 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,392 Biotechnology companies, OSE Immunotherapeutics ranks better than 80.53% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-25), OSE Immunotherapeutics's 3-1 Month Momentum % is -61.81%.
The industry rank for OSE Immunotherapeutics's 3-1 Month Momentum % or its related term are showing as below:
ORPOF's 3-1 Month Momentum % is ranked better than 80.53% of 1392
companies
in the Biotechnology industry
Industry Median: -10.615
vs ORPOF: -61.81
OSE Immunotherapeutics (OTCPK:ORPOF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
OSE Immunotherapeutics 3-1 Month Momentum % Related Terms
ORPOF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, OSE Immunotherapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's 3-1 Month Momentum % falls into.
OSE Immunotherapeutics (OTCPK:ORPOF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSE Immunotherapeutics (ORPOF) has a 3-1 Month Momentum % of -61.81% as of Jul. 25, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on OSE Immunotherapeutics and its competitors. According to the industry distribution chart, OSE Immunotherapeutics ranks #271 out of 1392 companies in the Biotechnology industry, placing it in the top 19.5%.
Is OSE Immunotherapeutics' 3-1 Month Momentum % too high?
OSE Immunotherapeutics' current 3-1 Month Momentum % is -61.81%. Based on the distribution chart, OSE Immunotherapeutics ranks #271 out of 1392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #271 out of 1392 companies for 3-1 Month Momentum %. This places OSE Immunotherapeutics in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on OSE Immunotherapeutics and its competitors. OSE Immunotherapeutics's current 3-1 Month Momentum % is -61.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.06, compared to a current price of $4.43 — trading 115% above its estimated fair value. The current 3-1 Month Momentum % is -61.81%. OSE Immunotherapeutics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current 3-1 Month Momentum % is -61.81% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 115% above its estimated GF Value™ of $2.06.
GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.
Key valuation signals for ORPOF:
3-1 Month Momentum %: -61.81%
GF Value™: $2.06 vs. price of $4.43 (115% above fair value)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
51GF Score
Get the complete analysis for ORPOF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
